Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for familial chylomicronemia syndrome and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of TTR amyloidosis; Olezarsen for patients with severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Tofersen to inhibit the production of superoxide dismutase 1. In addition, the company develops medicines for metabolic diseases, infectious diseases, renal diseases, ophthalmic diseases, and cancer. It has a strategic collaboration with Biogen Inc.; and collaboration and license agreement with AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis AG, Roche, Janssen Biotech, Inc., and Flamingo Therapeutics, Inc. Ionis Pharmaceuticals, Inc. was founded in 1989 and is based in Carlsbad, California.

Ionis Pharmaceuticals, Inc.

BASE mRNA facility focuses on messenger RNA design, manufacturing, and research. They provide end-to-end research services to design, manufacture, and test new mRNA medicines.

BASE mRNA facility

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1). In addition, the company is developing givosiran for the treatment of adolescent patients with AHP; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; ALN-AAT02 for the treatment of AAT deficiency-associated liver disease; ALN-HBV02 to treat chronic HBV infection; Zilebesiran to treat hypertension; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia and rare bleeding disorders, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1 and recurrent renal stones, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Sanofi Genzyme to discover, develop, and commercialize RNAi therapeutics. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Alnylam Pharmaceuticals, Inc.

DVLP is building a new infrastructure for drug development by digitizing drug assets, financing, and development workflows to accelerate the process of turning molecules into medicines.

DVLP

Ionis is a company focused on the discovery, development, and delivery of genetic medicines.

Ionis

For three decades, Ionis has invented medicines that bring better futures to people with serious diseases. Ionis currently has five marketed medicines and a leading pipeline in neurology, cardiology, and other areas of high patient need. As the pioneer in RNA-targeted medicines, Ionis continues to drive innovation in RNA therapies in addition to advancing new approaches in gene editing. A deep understanding of disease biology and industry-leading technology propels our work, coupled with a passion and urgency to deliver life-changing advances for patients.

The U.S. Food and Drug Administration accepted our New Drug Application for the treatment of familial chylomicronemia syndrome (#FCS) and granted Priority Review. In addition, enrollment completed in the Phase 3 severe hypertriglyceridemia (#sHTG) clinical program. 
 
Read more: https://lnkd.in/epHKFCF3

Today, we announced an expanded license agreement with Otsuka Pharmaceutical Co., Ltd. under which Otsuka will support commercialization in Asia Pacific for our investigational prophylactic medicine for hereditary angioedema (#HAE).
 
Read more about this announcement and what it means for people living with this serious #RareDisease: https://lnkd.in/en24U9EJ

Asian Pacific Islander Desi American (APIDA) Heritage Month is a time to honor the APIDA communities’ experiences, histories and cultures. We kicked off celebrations with our second annual employee-contributed art exhibit hosted by our DEI Advocates ERG. All Ions connected to the APIDA community were invited to share their art and culture at the event. Scroll through to see and hear more from our Ions.

At Ionis, we stand firm in our commitment to steward an inclusive and supportive environment where everyone can thrive. We embrace the authenticity, diversity and unique perspectives of our LGBTQ+ colleagues - during Pride month and throughout the year. By championing these values, we strengthen our teams, drive innovation and build a stronger, more compassionate organization for all. #HappyPride 

(Video taken June 4th at our flag raising on our Carlsbad campus and followed by a Pride celebration lunch with activities organized by our LGBTQIA+ ERG.)

Last week, we had the incredible opportunity to co-sponsor the second annual ‘LGBTQ+ Scholars in STEM’, a San Diego-based event aimed at empowering the next generation of biotech leaders! It was an evening filled with insightful discussions and meaningful connections.
 
Our very own JP Mac Donald and Archit Rastogi spoke on panels alongside biotech leaders from our hosts Illumina as well as Bristol Myers Squibb, Crinetics Pharmaceuticals, Takeda, Travere Therapeutics, and OUTbio San Diego. Panelists delved into the intricacies of making the leap from academia to industry, while also shedding light on LGBTQ+ inclusivity in the workplace.
 
Events like these are crucial for fostering diversity and inclusion in our industry and provide a platform for LGBTQIA+ individuals to share their unique career experiences and insights. It's truly inspiring to witness the passion and drive that these individuals bring to their work, reminding us of the importance of creating inclusive environments where everyone can thrive.
 
A big thank you to everyone who joined us for this event and continues to champion diversity and inclusion in STEM.

#GlobalFattyLiverDay, led by Global Liver Institute, is an annual moment in time to educate about fatty liver disease, which impacts over 115 million people globally. 

#FattyLiverDisease may lead to serious complications like cirrhosis, liver cancer or the need for a liver transplant. Due to the lack of obvious symptoms, people impacted by this condition may struggle to receive a diagnosis.

Join us in raising awareness of this progressive condition.

Metric
Company Name	Ionis Pharmaceuticals, Inc.	BASE mRNA facility	Alnylam Pharmaceuticals, Inc.	DVLP
Symbol	IONS		ALNY
MSH ID	COM:IONIS	AU:ORG:BASEFACILITY	COM:ALNYLAM	COM:DVLPMEDICINES
Market	STOCKS	PRIVATE	STOCKS	PRIVATE
Sector	Healthcare	Healthcare & Health Services	Healthcare	Healthcare & Health Services
Industry	Biotechnology	Biotechnology	Biotechnology	Pharmaceuticals
Country	US	AU	US	US
Stage
Employee Count	927		2.10K
Website	ionispharma.com	basefacility.org.au	alnylam.com	dvlpmedicines.com
LinkedIn	ionis-pharmaceuticals	base-facility		dvlpmedicines
Founders

Metric
Market Cap	6.98B	32.60B
Enterprise Value
Monthly Web Traffic		55.97K	133
Web Traffic Growth		0.89	-0.55
Valuation
Raised Capital		900M

Metric
Revenue	787.65M	1.83B
Revenue (LTM)
Revenue (NTM)
Gross Profit	778.51M	1.52B
EBITDA	-322.84M	-228.12M
Operating Income	-353.73M	-282.18M
Net Income	-366.29M	-440.24M
EPS	-2.56	-3.52
Diluted EPS	-2.56	-3.52
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.99	0.87
Operating Profit Margin	-0.45	0.04
EBITDA Margin	-0.41	-0.12
Net Profit Margin	-0.45	-0.03
Return on Equity	-0.90	1.67
Return on Assets	-0.12	-0.02
Return on Capital Employed	-0.14	0.03

COM:IONIS

Ionis

Last Close

33.03

12/03 20:00

Market Cap

6.98B

Beta: -

Volume Today

1.76M

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-17.34	-42.10
P/B Ratio	22.46	-129.43
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	9.75	16.84
EV Multiple	-11.30	326.32

Metric
Days Sales Outstanding	84.28	68.92
Days Payables Outstanding	204.95	97.72
Days Inventory Outstanding	1.14K	128.53
Operating Cycle	1.19K	187.09
Cash Conversion Cycle	397.63	104.98
Asset Turnover	0.30	0.58

Metric
Operating Cash Flow	-307.51M	104.16M
Free Cash Flow	-335.52M	41.95M
Cash Flow to Debt	-0.18	0.15
Operating Cash Flow/Sales	-0.39	0.16
Free Cash Flow Yield	-0.06	-0.00

Metric
Cash & Equivalents	399.27M	812.69M
Accounts Receivable	-72.06M	-87.94M
Inventory	28.43M	89.15M
Goodwill
Debt to Capitalization	0.87	1.20
Debt to Assets	0.49	0.34
Current Ratio	2.82	3.14
Quick Ratio	22.12	3.07

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.13	0.13
R&D to Revenue	1.55	0.58
SG&A to Revenue	0.32	0.35